• Recruitment continues in the complementary cohorts of the IMMUNICY-1 dose-escalation Phase 1 trial for the allogeneic shRNA-based CAR T candidate, CYAD-211, for patients with relapsed/refractory Multiple Myeloma (MM r /r)
• Dialogue with regulatory agencies continues regarding the Phase 1 clinical trial, CYAD-101-002, currently on clinical hold
Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the research and development of CAR T (Chimeric Antigen Receptor) cell therapies based on cells for the treatment of cancer, announced an update of its financial results as well as its recent operational developments for the fiscal quarter ended March 31, 2022.